The cost-effectiveness analysis of adjuvanted influenza vaccines (aIV) over standard vaccines (sIV) in older adults presents significant economic benefits, potentially reshaping market dynamics in the Netherlands. Pharma companies must adapt their marketing and reimbursement strategies to leverage these findings, particularly as they pertain to aging populations. Regulatory context from FDA (FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)) supports the near-term read. Assessment grounded in 20 ranked evidence items (11 high-relevance).